Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Sep 1;18(1):195.
doi: 10.1186/s13075-016-1094-y.

The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial

George P Karamanolis  1 , Stylianos Panopoulos  2 , Konstantinos Denaxas  3 , Anastasios Karlaftis  3 , Alexandra Zorbala  2 , Dimitrios Kamberoglou  3 , Spiros D Ladas  3 , Petros P Sfikakis  2
Affiliations
Clinical Trial

The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial

George P Karamanolis et al. Arthritis Res Ther. .

Abstract

Background: Acute administration of the oral 5-HT1A receptor agonist buspirone, which is commonly used as an anxiolytic drug, may improve compromised lower esophageal sphincter function. In an open-label trial we assessed the effects of buspirone on esophageal motor function and symptoms in patients with esophageal involvement associated with systemic sclerosis (SSc).

Methods: Thirty consecutive patients with SSc and symptomatic esophageal involvement, despite treatment with proton pump inhibitors, underwent high resolution manometry and chest computed tomography for assessment of motor function and esophageal dilatation, respectively. Regurgitation, heartburn, dysphagia, and chest pain severity was subjectively scored by visual analog scales. Manometric parameters (primary endpoint) and symptom severity (secondary endpoint) were re-examined after 4-week daily administration of 20 mg buspirone. Other medications remained unchanged.

Results: Eight patients did not complete the trial because of buspirone-associated dizziness (n = 2), or nausea (n = 2), or reluctancy to undergo final manometry. In the remaining 22 patients lower esophageal sphincter (LES) resting pressure increased from 7.7 ± 3.9 to 12.2 ± 4.6 mmHg (p = 0.00002) after buspirone administration; other manometric parameters did not change. Statistical analysis revealed negative correlation between individual increases in resting LES pressure and supra-aortic esophageal diameter (r = -0.589, p = 0.017), suggesting a more beneficial effect in patients with less severely affected esophageal function. Heartburn and regurgitation scores decreased at 4 weeks compared to baseline (p = 0.001, and p = 0.022, respectively).

Conclusion: Our findings warrant more conclusive evaluation with a double-blind controlled study; however, buspirone could potentially be given under observation for objective improvement in all patients with SSc who report reflux symptoms despite undergoing standard treatment.

Trial registration: ClinicalTrials.gov Identifier: NCT02363478 Registered: 21-02-2014.

Keywords: Buspirone; Esophageal motility; Reflux symptoms; Scleroderma.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Change in lower esophageal sphincter (LES) pressure in each individual at baseline and after 4-week daily oral administration of 20 mg buspirone
See this image and copyright information in PMC

References

    1. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117:557–67. doi: 10.1172/JCI31139. - DOI - PMC - PubMed
    1. Clements PJ, Becvar R, Drosos AA, Ghattas L, Gabrielli A. Assessment of gastrointestinal involvement. Clin Exp Rheumatol. 2003;21(Suppl 29):S15–8. - PubMed
    1. Ebert EC. Esophageal disease in scleroderma. J Clin Gastroenterol. 2006;40:769–75. doi: 10.1097/01.mcg.0000225549.19127.90. - DOI - PubMed
    1. Ntoumazios SK, Voulgari PV, Potsis K, Koutis E, Tsifetaki N, Assimakopoulos DA. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Semin Arthritis Rheum. 2006;36:173–81. doi: 10.1016/j.semarthrit.2006.08.002. - DOI - PubMed
    1. Sallam H, McNearney TA, Chen JD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma) Aliment Pharmacol Ther. 2006;23:691–712. doi: 10.1111/j.1365-2036.2006.02804.x. - DOI - PubMed

Publication types

Substances

Associated data